Targeting TNBC: Fisetin and Cabazitaxel NLCs synergistic effects on cell lines and tumor suppression in mice

Document Type : Research Paper

Authors

1 Department of Pharmaceutics, Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun-248007, Uttarakhand, India.

2 LCIT School of Pharmacy, Near High Court, Village-Bodri, Bilaspur, C.G 495220, India

10.22038/nmj.2025.80903.2002

Abstract

Objective(s): Although various treatments for Triple-Negative Breast Cancer (TNBC) and its associated diseases exist, the Nanostructured Lipid Carrier (NLC) system has garnered significant attention in recent years due to its advantageous properties. However, drugs administered in combination therapy tend to have a more potent effect than those administered in monotherapy. This study evaluated the anticancer efficacy of Fis-NLCs and CBZ-NLCs on TNBC cell lines, MDA-MB-468 and MCF-7, by assessing cytotoxicity, cell migration, and apoptosis induced by both Fis-NLCs and CBZ-NLCs, both individually and in combination.
Materials and Methods: In vivo, experiments on Swiss albino mice were conducted to evaluate the efficacy of drug-loaded NLCs in reducing tumor volume and hemotoxicity.
Results: Cytotoxicity assays revealed that, against MDA-MB-468 cells, the IC50 values at 24 hours were 10.85±1.39 µM for Fis-NLCs and 4.25±0.78 µM for CBZ-NLCs, while at 48 hours, the IC50 values were 3.48±0.74 µM for Fis-NLCs and 1.36±0.3 µM for CBZ-NLCs. For MDA-MB-231 cells, IC50 values at 24 hours were 10.84±0.97 µM for Fis-NLCs and 5.07±1.46 µM for CBZ-NLCs, and at 48 hours, 3.18±0.67 µM for Fis-NLCs and 3.38±1.05 µM for CBZ-NLCs. Additionally, CBZ-NLCs decreased the inhibitory concentration of Fis-loaded NLCs, inhibiting 50% of the cancer cell population at concentrations of 2.52 ± 0.57 µM, 2.17 ± 0.24 µM, and 2.12 ± 0.45 µM after 48 hours.
Conclusion: Furthermore, in vivo studies have demonstrated that NLC-based drug delivery effectively reduces tumor size in mice compared to pure drugs. When Fis-NLCs were combined with CBZ-NLCs, a synergistic effect was observed, leading to enhanced tumor growth inhibition, improved pharmacokinetics, and reduced hemotoxicity in mice.

Keywords


  1. https://www.who.int/cancer/country-profiles/en/.
  2. Rose DP, Vona-Davis L. Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas. 2010; 66:33–38
  3. Malorni L, Shetty PB, De Angelis C, Hilsenbeck S, Rimawi MF, Elledge R, Osborne CK, De Placido S, Arpino G. Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res Treat. 2012;136:795–804
  4. Guarneri V, Dieci MV, Conte P. Relapsed triple-negative breast cancer: Challenges and treatment strategies. Drugs. 2013;73:1257–1265
  5. Lehmann BD, Jovanović B, Chen X, Estrada M V., Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One. 2016; 11:e0157368
  6. Chauhan AS, Kathuria S, Gehlot A, Sunil G. Revolutionizing Drug Discovery: Unleashing AI’s Potential in Pharmaceutical Innovation. InInternational Conference on Recent Trends in Image Processing and Pattern Recognition. Cham: Springer Nature Switzerland. 2023; 39-50.
  7. THE 17 GOALS | Sustainable Development. https://sdgs.un.org/goals. Accessed 30 Jul 2024
  8. Alshahrani MY, Uthirapathy S, Kumar A, Oghenemaro EF, Roopashree R, Lal M, et al. NK Cell-Based Cancer Immunotherapies: Current Progress, Challenges and Emerging Opportunities. J Biochem Mol Toxicol. 2024; 38:e70044
  9. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clinical Cancer Research. 2007; 13:4429–4434
  10. Gatabi ZR, Saeedi M, Morteza-Semnani K, Rahimnia SM, Yazdian-Robati R, Hashemi SMH. Green preparation, characterization, evaluation of anti-melanogenesis effect and in vitro/in vivo safety profile of kojic acid hydrogel as skin lightener formulation. J Biomater Sci Polym Ed. 2022; 33:2270–2291
  11. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clinic Investigat. 2011; 121:2750–2767
  12. Turner NC, Reis-Filho JS. Tackling the diversity of Triple-negative breast cancer. Clinic Cancer Res. 2013; 19:6380–6388
  13. Zheng R, Han S, Duan C, Chen K, You Z, Jia J, Lin S, Liang L, Liu A, Long H, Wang S. Role of taxane and anthracycline combination regimens in the management of advanced breast cancer: a meta-analysis of randomized trials. Medicine. 2015; 94(17):e803.
  14. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004; 4:253–265.
  15. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol. 2012; 30:679–692
  16. Hashemi SMH, Enayatifard R, Akbari J, Saeedi M, Seyedabadi M, Morteza-Semnani K, et al. Venlafaxine HCl encapsulated in niosome: green and eco-friendly formulation for the management of pain. AAPS Pharm Sci Tech. 2022; 23:1–14
  17. Kümmel S, Paepke S, Huober J, Schem C, Untch M, Blohmer JU, Eiermann W, Gerber B, Hanusch C, Hilfrich J, Jackisch C. Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). Eur J Cancer. 2017; 84:1–8
  18. Yardley DA, Hart LL, Ward PJ, Wright GL, Shastry M, Finney L, et al. Cabazitaxel Plus Lapatinib as Therapy for HER2 + Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding Study. Clin Breast Cancer. 2018; 18:e781–e787
  19. Kommineni N, Saka R, Bulbake U, Khan W. Cabazitaxel and thymoquinone co-loaded lipospheres as a synergistic combination for breast cancer. Chem Phys Lipids. 2019;224:104707.
  20. Reddy DM, Jain V. An overview on medicinal plants for the treatment of acne. J Critic Rev. 2019; 6:7–14
  21. Dinakar YH, Kumar H, Mudavath SL, Jain R, Ajmeer R, Jain V. Role of STAT3 in the initiation, progression, proliferation and metastasis of breast cancer and strategies to deliver JAK and STAT3 inhibitors. Life Sci. 2022; 309:120996
  22. Siri Sindhura DK, Jain V. Challenges in formulating herbal cosmetics. Inter J Appl Pharm. 2018; 10:47–53
  23. Imran M, Saeed F, Gilani SA, Shariati MA, Imran A, Afzaal M, et al. Fisetin: An anticancer perspective. Food Sci Nutr. 2021; 9:3–16
  24. Kubina R, Krzykawski K, Kabała-Dzik A, Wojtyczka RD, Chodurek E, Dziedzic A. Fisetin, a potent anticancer flavonol exhibiting cytotoxic activity against neoplastic malignant cells and cancerous conditions: a scoping, comprehensive review. Nutrients. 2022.
  25. Sun X, Ma X, Li Q, Yang Y, Xu X, Sun J, Yu M, Cao K, Yang L, Yang G, Zhang G. Anti‑cancer effects of fisetin on mammary carcinoma cells via regulation of the PI3K/Akt/mTOR pathway: In vitro and in vivo studies. Int J Mol Med. 2018; 42:811–820
  26. Yousefzadeh MJ, Zhu YI, McGowan SJ, Angelini L, Fuhrmann-Stroissnigg H, Xu M, Ling YY, Melos KI, Pirtskhalava T, Inman CL, McGuckian C. Fisetin is a senotherapeutic that extends health and lifespan. EBioMed. 2018; 36:18–28.
  27. S P, Kumar H, C R, A SB, K N, Ajmeer R, Jain V. Protective Effects of Sauropus Androgynus Leaf Extract against Isoproterenol Induced Cardiotoxicity. Cardiovasc Toxicol. 2022; 22:579–591
  28. Kesharwani SS, Mallya P, Kumar VA, Jain V, Sharma S, Dey S. Nobiletin as a molecule for formulation development: an overview of advanced formulation and nanotechnology-based strategies of nobiletin. AAPS Pharm Sci Tech. 2020; 21:226
  29. Kesharwani SS, Jain V, Dey S, Sharma S, Mallya P, Kumar VA. An overview of advanced formulation and nanotechnology-based approaches for solubility and bioavailability enhancement of silymarin. J Drug Deliv Sci Technol. 2020; 60:102021
  30. Teng Z, Yu M, Ding Y, Zhang H, Shen Y, Jiang M, et al. Preparation and characterization of nimodipine-loaded nanostructured lipid systems for enhanced solubility and bioavailability. Inter J Nanomed. 2019; 14:119–133
  31. Elmowafy M, Al-Sanea MM. Nanostructured lipid carriers (NLCs) as drug delivery platform: Advances in formulation and delivery strategies. Saudi Pharm J. 2021; 29:999–1012.
  32. Paliwal R, Babu RJ, Palakurthi S. Nanomedicine Scale-up Technologies: Feasibilities and Challenges. Ageing Int. 2014; 15:1527–1534
  33. Jain V, Kumar H, Chand P, Jain S, S P. Lipid‐Based Nanocarriers as Drug Delivery System and Its Applications. In: Nanopharmaceutical Advanced Delivery Systems. 2021;1–29
  34. Chauhan I, Yasir M, Verma M, Singh AP. Nanostructured lipid carriers: A groundbreaking approach for transdermal drug delivery. Adv Pharm Bull. 2020; 10:150–165
  35. Akbari J, Saeedi M, Ahmadi F, Hashemi SMH, Babaei A, Yaddollahi S, et al. Solid lipid nanoparticles and nanostructured lipid carriers: a review of the methods of manufacture and routes of administration. Pharm Dev Technol. 2022; 27:525–544
  36. Garg J, Pathania K, Sah SP, Pawar SV. Nanostructured lipid carriers: a promising drug carrier for targeting brain tumours. Futur J Pharm Sci. 2022.
  37. Chand P, Kumar H, Badduri N, Gupta NV, Bettada VG, Madhunapantula SRV, et al. Design and evaluation of cabazitaxel loaded NLCs against breast cancer cell lines. Colloids Surf B Biointerfaces. 2021; 199:111535
  38. Kumar H, Chand P, Pachal S, Mallick S, Jain R, Madhunapantula SR V, et al. (2023) Fisetin-Loaded Nanostructured Lipid Carriers: Formulation and Evaluations against Advanced and Metastatic Melanoma. Mol Pharm. 2023 20:6035–6055
  39. Madhunapantula S V, Sharma A, Gowda R, Robertson GP. Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma. Pigment Cell Melanoma Res. 2013; 26:886–899
  40. Vrignaud P, Sémiond D, Lejeune P, Bouchard H, Calvet L, Combeau C, et al. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clinic Cancer Res. 2013; 19:2973–2983
  41. Zhong T, He B, Cao HQ, Tan T, Hu HY, Li YP, et al. Treating breast cancer metastasis with cabazitaxel-loaded polymeric micelles. Acta Pharmacol Sin. 2017; 38:924–930
  42. Anantharaju PG, Reddy BD, Padukudru MA, Kumari Chitturi CHM, Vimalambike MG, Madhunapantula SR V. Naturally occurring benzoic acid derivatives retard cancer cell growth by inhibiting histone deacetylases (HDAC). Cancer Biol Ther. 2017; 18:492–504
  43. Jasim SA, Ahmed AT, Kubaev A, Kyada A, Alshahrani MY, Sharma S, et al. Exosomal microRNA as a key regulator of PI3K/AKT pathways in human tumors. Med Oncol. 2024 41:11 41:1–17
  44. Lin N, Huang C, Tian J, Tao J, Zhang J, Yang L, Li Y, Liu Y, Chen S, Shen G, Li J. The expression of endothelin receptor B in melanoma cells A375 and Sk-mel-1 and the proliferative effects of endothelin 3 on A375 cells. J Huazhong Uni Sci Tech. 2007;27: 611-613.
  45. Huang L, Jiang Y, Chen Y. Predicting Drug Combination Index and Simulating the Network-Regulation Dynamics by Mathematical Modeling of Drug-Targeted EGFR-ERK Signaling Pathway. Sci Rep. 2017.
  46. Ravichandran N, Suresh G, Ramesh B, Vijaiyan Siva G. Fisetin, a novel flavonol attenuates benzo(a)pyrene-induced lung carcinogenesis in Swiss albino mice. Food Chem Toxicol. 2011; 49:1141–1147
  47. Chen Y, Zhang W, Huang Y, Gao F, Fang X. In vivo biodistribution and anti-tumor efficacy evaluation of doxorubicin and paclitaxel-loaded pluronic micelles decorated with c(RGDyK) peptide. PLoS One. 2016.
  48. Ragelle H, Crauste-Manciet S, Seguin J, Brossard D, Scherman D, Arnaud P, et al. Nanoemulsion formulation of fisetin improves bioavailability and antitumour activity in mice. Inter J Pharm. 2012; 427:452–459
  49. Plichta JK, Thomas SM, Vernon R, Fayanju OM, Rosenberger LH, Hyslop T, et al. Breast cancer tumor histopathology, stage at presentation, and treatment in the extremes of age. Breast Cancer Res Treat. 2020; 180:227–235
  50. Shrivastava S, Singh N, Nigam AK, Chandel SS, Shrivastava R, Kumar S. Comparative study of hematological parameters along with effect of chemotherapy and radiotherapy in different stages of breast cancer. Int J Res Med Sci. 2016; 5:311.
  51. Chou RH, Hsieh SC, Yu YL, Huang MH, Huang YC, Hsieh YH. Fisetin inhibits migration and invasion of human cervical cancer cells by down-regulating urokinase plasminogen activator expression through suppressing the p38 MAPK-dependent NF-κB signaling pathway. PLoS One. 2013.
  52. Thangavelu L, Imran M, Alsharari SH, Abdulaziz AM, Alawlaqi AM, Kamal M, Rekha MM, Kaur M, Soothwal P, Arora I, Kumar MR. Exploring hypoxia-induced ncRNAs as biomarkers and therapeutic targets in lung cancer. Pathol Res Pract. 2024:155613.
  53. Guada M, Lasa-Saracíbar B, Lana H, Del Carmen Dios-Viéitez M, Blanco-Prieto MJ. Lipid nanoparticles enhance the absorption of cyclosporine A through the gastrointestinal barrier: In vitro and in vivo studies. Int J Pharm. 2016;500(1-2):154–161.
  54. Beloqui A, Solinís MÁ, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine: Nanotechnology, biology and medicine. Nanomedicine. 2016;12(1):143-161.
  55. Li Q, Cai T, Huang Y, Xia X, Cole SP, Cai Y. A review of the structure, preparation, and application of NLCs, PNPs, and PLNs. Nanomaterials. 2017 May 27;7(6):122.
  56. Nanoemulsion formulation of fisetin improves bioavailability and antitumour activity in mice.
  57. Zhang L, Wang H, Zhou Y, Zhu Y, Fei M (2018) Fisetin alleviates oxidative stress after traumatic brain injury via the Nrf2-ARE pathway. Neurochem Int. 118:304–313
  58. Kumar H, Kumar RM, Bhattacharjee D, Somanna P, Jain V. Role of Nrf2 Signaling Cascade in Breast Cancer: Strategies and Treatment. Front Pharmacol. 2022;13:720076
  59. Poornashree M, Kumar H, Ajmeer R, Jain R, Jain V. Dual role of Nrf2 in cancer: molecular mechanisms, cellular functions and therapeutic interventions. Mol Biol Rep. 2023;50(2):1871-1883.
  60. Damsky WE, Theodosakis N, Bosenberg M. Melanoma metastasis: New concepts and evolving paradigms. Oncogene. 2014;33(19):2413–2422.